Strengthening Oncology–Ophthalmology Communication for Management of ADC Associated Ocular Toxicities

In this segment, the discussion shifts to practical strategies for improving communication between oncologists and ophthalmology providers when managing ocular toxicities associated with antibody–drug conjugates (ADCs). The ophthalmologist emphasizes that while corneal specialists may offer deep expertise, most referrals will be seen by general ophthalmologists or optometrists—making clear, structured communication essential. She highlights the value of baseline eye exams required for some ADCs, which help establish early patient–provider relationships and enable faster access if complications arise. For ADCs without baseline requirements, the expert faculty notes the importance of ensuring ophthalmologists receive clear, drug-specific guidance. Many ADC manufacturers provide standardized eye-care provider forms outlining expected toxicities and what to monitor, which both educates eye-care clinicians and facilitates consistent reporting back to oncology teams. Because ophthalmologic terminology can be highly specialized, these structured tools help bridge language gaps, ensuring oncologists receive actionable, clinically relevant information to guide treatment decisions.